New hope for Tough-to-Treat head & neck cancers
NCT ID NCT06725368
Summary
This study is testing a combination of three drugs (carboplatin, paclitaxel, and cetuximab) for adults with head and neck cancer that has returned or spread after their first treatment with pembrolizumab immunotherapy. The main goal is to see how well this three-drug combo shrinks tumors and controls the disease. Researchers will also closely monitor side effects and quality of life for the 46 participants over 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Besançon
RECRUITINGBesançon, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier de Colmar
RECRUITINGColmar, 68024, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Paul Strauss
RECRUITINGStrasbourg, 67033, France
Contact Email: •••••@•••••
Contact
Contact
Contact
-
Centre hospitalier Régional de Metz-Thionville
RECRUITINGArs-Laquenexy, 57085, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut de cancérologie de Lorraine
RECRUITINGVandœuvre-lès-Nancy, 54519, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.